Currently, there are 380.70M common shares owned by the public and among those 373.50M shares have been available to trade.
The company’s stock has a 5-day price change of -8.65% and -40.39% over the past three months. VRT shares are trading -31.33% year to date (YTD), with the 12-month market performance up to 8.38% higher. It has a 12-month low price of $62.40 and touched a high of $155.84 over the same period. VRT has an average intraday trading volume of 9.51 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -20.80%, -31.56%, and -24.11% respectively.
Institutional ownership of Vertiv Holdings Co (NYSE: VRT) shares accounts for 82.95% of the company’s 380.70M shares outstanding.
It has a market capitalization of $29.71B and a beta (3y monthly) value of 1.65. The stock’s trailing 12-month PE ratio is 60.60, while the earnings-per-share (ttm) stands at $1.29. The company has a PEG of 2.58 and a Quick Ratio of 1.25 with the debt-to-equity ratio at 1.29. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.14% over the week and 7.28% over the month.
Analysts forecast that Vertiv Holdings Co (VRT) will achieve an EPS of 0.61 for the current quarter, 0.9 for the next quarter and 4.45 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.59 while analysts give the company a high EPS estimate of 0.59. Comparatively, EPS for the current quarter was 0.43 a year ago. Earnings per share for the fiscal year are expected to increase by 25.89%, and 23.01% over the next financial year.
Looking at the support for the VRT, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on March 07, 2025, with the firm’s price target at $121. Melius coverage for the Vertiv Holdings Co (VRT) stock in a research note released on January 28, 2025 offered a Hold rating with a price target of $125. Morgan Stanley was of a view on January 06, 2025 that the stock is Overweight, while Barclays gave the stock Equal Weight rating on December 12, 2024, issuing a price target of $142. UBS on their part issued Buy rating on November 13, 2024.
